Degree of functional impairment and outcome in DAWS+
| Functional impairment of DAWS+ patients | ||||
| Mild to moderate: limited to demanding activities or if it had some impact on the patient's and family daily life | ||||
| n | LD-LEDD (mg) p1 | DA-LEDD (mg) p2 | Cumulative DA-LEDD (mg) p3 | Total LEDD at withdrawal p4 |
| 7 | 963 (562) (300–1800) | 226 (167) (60–480) | 1445 (1453) (15–3525) | 1189 (558) (420–1900) |
| Severe: considerable disruption of the patient's and family daily life or inability to perform basic activities of daily life | ||||
| n | LD-LEDD (mg) | DA-LEDD (mg) | Cumulative DA-LEDD (mg) | Total LEDD at withdrawal |
| 6 | 702 (328) (300–1200) | 255 (120) (120–450) | 1208 (679) (600–2475) | 957 (306) (560–1320) |
| Outcome of DAWS patients | ||||
| Recovery <6 months | ||||
| n | LD-LEDD (mg) p5 | DA-LEDD (mg) p6 | Cumulative DA-LEDD (mg) p7 | Total LEDD at withdrawal p8 |
| 8 | 930 (540) (300–1800) | 213 (126) (60–400) | 1274 (1391) (15–3525) | 1143 (549) (420–1900) |
| Recovery >6 months <1 year | ||||
| 0 | – | – | – | – |
| Recovery >1 year | ||||
| 3 | 750 (409) (400–1200) | 350 (199) (120–480) | 1710 (662) (1325–2475) | 1100 (220) (880–1320) |
| Unable to tolerate DA withdrawal due to DAWS symptoms | ||||
| 2 | 633 (329) (400–866) | 180 (28) (160–200) | 1019 (299) (807–1231) | 813 (357) (560–1066) |
Results are given as: mean (SD), (range).
ADL, activities of daily living; DA, dopamine agonist; DAWS, dopamine agonist withdrawal syndrome; LD, levodopa; LEDD, levodopa equivalent daily dose.
Mann–Whitney U test: p1: 0.53; p2: 0.53; p3: 0.94; p4: 0.44; Kruskal–Wallis: p5: 0.86; p6: 0.44; p7: 0.31; p8: 0.49.